Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Locally Advanced Rectal Cancer - a Multicenter, Single-arm, Open-label Clinical Trail

Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Locally Advanced Rectal Cancer

Evaluation of the efficacy and safety of interleucin-2 combined with PD-1 monoclonal antibody and CAPOX in preoperative neoadjuvant therapy for locally advanced rectal cancer - a multicenter, single-arm, open-label clinical trail.

Study Overview

• Status: Not yet recruiting
• Conditions: Locally Advanced Rectal Adenocarcinoma
• Intervention / Treatment: Drug: Sintilimab with Interleukin-2+CAPOX

Detailed Description

The global incidence rate of rectal cancer is approximately 732,000 cases/year, of which a significant proportion is locally advanced rectal cancer (i.e., T3-4 or N+). Currently, for locally advanced rectal cancer, the NCCN guidelines recommend treatment with neoadjuvant radiotherapy and chemotherapy + total mesorectal excision + adjuvant chemotherapy, reducing the local recurrence rate of locally advanced rectal cancer from over 30% to less than 10%. However, this treatment mode still has a low overall sphincter preservation rate, a high distant metastasis rate, and limited overall survival (OS) benefits. In recent years, the emergence of total neoadjuvant therapy (TNT) strategies, including induction chemotherapy + concurrent chemoradiotherapy + surgery, concurrent chemoradiotherapy + consolidation chemotherapy (two or even three drugs) + surgery, and concurrent chemoradiotherapy + consolidation immunotherapy combined with chemotherapy + surgery, have all improved the long-term prognosis of locally advanced rectal cancer to varying degrees. However, the TNT mode is not suitable for all rectal cancer patients. For patients with low or moderate-risk rectal cancer or those who cannot tolerate intensive radiotherapy and chemotherapy, TNT increases the potential risk of overtreatment and associated toxicity.

The emergence of immunotherapy, including adoptive cell transfer (ACT) and immune checkpoint inhibitors (ICB), provides new insights into the treatment of locally advanced rectal cancer. However, most colorectal cancer patients have a limited response to immunotherapy. For ACT, many clinical studies report that exogenously infused antitumor T cells have poor tumor tissue infiltration, resulting in extremely limited immune responses. This inefficiency in T cell delivery may be due to high interstitial fluid pressure, pathological vascular networks, tumor-associated fibroblasts, or the "physical barrier" of the extracellular matrix (ECM), as well as the immunosuppressive tumor microenvironment. As for immune checkpoint inhibitors (ICIs), especially PD-1/PD-L1 targeted therapies, they have shown significant promise in the treatment of various solid tumors, including breast cancer, lung cancer, gastric cancer, and colorectal cancer. Studies such as CheckMate-142 and KEYNOTE-177 have confirmed the excellent efficacy of PD-1/PD-L1 inhibitors in the treatment of colorectal cancers with mismatch repair protein defects (dMMR) or high microsatellite instability (MSI-H). Institutions like the Memorial Sloan Kettering Cancer Center (MSKCC), Sun Yat-sen University Cancer Center, and the Sixth Affiliated Hospital of Sun Yat-sen University have conducted research on PD-1 inhibitors for neoadjuvant treatment of locally advanced rectal cancer, with complete remission rates as high as 75% to 100%. However, this patient population is very small, accounting for about 15% of early-stage colorectal cancers and only 5% of advanced colorectal cancers, especially less than 5% in rectal cancer. Meanwhile, microsatellite stable (MSS) patients make up the vast majority of colorectal cancers, and they benefit little from single-agent immunotherapy.

In this population, low tumor mutation burden (TMB) and insufficient immunogenicity, leading to inadequate immune cell infiltration, are considered one of the main resistance mechanisms to immunotherapy. Therefore, enhancing immune cell infiltration and boosting the therapeutic effect of immunotherapy in low-responsive colorectal cancer has significant clinical importance. Currently, some clinical experiments are being conducted in this area. For instance, radiotherapy theoretically synergizes with immunotherapy, possibly through the release of tumor antigens, remodeling of the immune microenvironment, and increasing antitumor immune responses, thus producing a combined therapeutic effect. Prospective phase II studies suggest that radiotherapy combined with immunotherapy achieves a higher pCR rate in pMMR/MSS locally advanced rectal cancer. Additionally, various immune cells in the tumor microenvironment (TME) can impair tumor immune responses, leading to tumor resistance to PD-1 therapy. Much evidence suggests that T cells in or near tumor tissues, although activated, cannot attack tumor cells. Thus, enhancing T cell tumor infiltration and activating their antitumor effects are key methods to enhance PD-1 therapy. Recent basic research results show that elevated levels of TGF-β and VEGF in tumor tissues suppress the aforementioned cytokines, enhancing tumor T cell infiltration and the efficacy of anti-PD-1 therapy. Moreover, a phase Ib clinical trial from Australia suggests that Pixatimod (a TLR9 agonist) combined with Nivolumab shows tolerability and clinical benefits in MSS mCRC patients, and researchers also observed pharmacodynamic changes and biomarker signals related to clinical benefits in the combination scheme. Similarly, another phase I clinical trial suggests that low molecular weight heparin (LMWH) enhances the efficacy of anti-PD-1 in MSS colorectal cancer by increasing CD8+T cell infiltration. These results highlight the immense prospects of PD-1 therapy combined with immune enhancement in antitumor immunotherapy.

IL-2 (Interleukin-2) is an essential cytokine, primarily produced by activated T cells. It plays a pivotal role in the immune system by promoting the growth and differentiation of T cells, enhancing the activity of cytotoxic T cells (CTLs) and natural killer cells (NK cells), and participating in immune responses against pathogens and tumors. In past tumor treatments, the primary application of IL-2 was to initiate and amplify the body's immune attack on tumors. In the treatment of certain diseases, such as malignant melanoma and renal cancer, monotherapy with appropriate doses of IL-2 has proven beneficial. For instance, a low dose of IL-2 20IU subcutaneous injection can induce immune activation while producing fewer clinical side effects. However, the complications of high-dose IL-2 treatment can be severe, including hypotension, respiratory distress, and renal impairment. Although IL-2 has some application in tumor immunotherapy, its efficacy is often limited, benefiting only a minority of patients. Current research is exploring ways to enhance the effectiveness of IL-2, including the development of novel IL-2 variants that improve the molecule's selectivity and stability, as well as combination therapies with other immune modulators, such as checkpoint inhibitors. In certain conditions, such as Lymphocytic Choriomeningitis Virus (LCMV) infection, the combined treatment of PD-1 and IL-2 has shown remarkable clinical efficacy. In vivo experiments indicate that, compared to PD-1 monotherapy, the combination of PD-1+IL-2 for LCMV significantly alters the differentiation program of PD-1+TCF1+ stem-like CD8+T cells, producing effector CD8+T cells distinct at the transcriptional and epigenetic levels, very similar to those observed after acute viral infections. Furthermore, in head and neck squamous cell carcinoma (HNSCC), a bispecific immune cytokine PD1-IL2v can notably activate immune cells, including NK cells and CD8+T cells, and inhibit the proliferation and metastasis of tumor cells. These discovered mechanisms elucidate the potential synergy between IL-2 treatment and PD-1 blockade, providing guidance and a theoretical foundation for our clinical trial using the combination of PD-1 and IL-2 in patients with locally advanced rectal cancer.

• Study Type: Interventional
• Enrollment (Estimated): 44
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: Yueming Sun, MD, PhD; Phone Number: 02568306026; Email: jssym@vip.sina.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Men and women aged 18-75 years old;
• ECOG performance status score of 0 or 1;
• Histologically proven colon or rectal adenocarcinoma;
• Clinical staged T3-T4 or any T with lymph node positive (N+);
• Adequate haematological, hepatic, and renal function: neutrophil count ≥1.5×109 /L; platelet count ≥75×109 /L; serum total bilirubin ≤1.5×upper normal limits (UNL); aspartate aminotransferase ≤2.5×UNL; alanine aminotransferase ≤2.5×UNL; serum creatinine≤1.5×UNL.

Exclusion Criteria:

• Metastatic disease (stage IV);
• Relapsed colorectal cancer;
• Complicated with active bleeding, perforation, or requiring emergency surgery;
• Previous systemic anticancer therapy for colorectal cancer disease
• Patients with other active concurrent non-colorectal cancer;
• Any active or history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications;
• Patients with interstitial lung disease, non-infectious pneumonia or uncontrollable systemic diseases (such as: diabetes, hypertension, pulmonary fibrosis and acute pneumonia);
• Patients with any Grade 2 or above toxicity as classified by the common terminology criteria for adverse events (CTCAE) (version 5.0) (except for anemia, alopecia and skin pigmentation) which is induced by previous treatment and has not subside;
• Previously received anti-programmed death-1 (PD-1) or its ligand (PD-L1) antibody, anti- cytotoxic T lymphocyte-associated antigen 4 (cytotoxic T-lymphocyte-associated Protein 4, CTLA-4) antibody Women in pregnancy or lactation;
• Known positive history or positive test for Human Immunodeficiency Virus or Acquired Immunodeficiency Syndrome (AIDS);
• History of known or suspected allergies to any related drugs used in the trial;
• Women who are pregnant or nursing.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Experimental group; Sintilimab with Interleukin-2+CAPOX	Drug: Sintilimab with Interleukin-2+CAPOX; Sintilimab with Interleukin-2+CAPOX

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
cCR	To evaluate whether neoadjuvant Sintilimab with Interleukin-2+CAPOX would significantly improve the Clinical complete response (cCR) proportion in patients with locally advanced rectal cancer	18 weeks

Secondary Outcome Measures

Outcome Measure	Time Frame
R0 resection rate R0 resection rate	1 day
pCR proportion	18 weeks
Major pathological response (MPR)	18 weeks
Disease-free survival (DFS) and overall survival (OS)	5 years

Collaborators and Investigators

• Sponsor: The First Affiliated Hospital with Nanjing Medical University

Study record dates

Study Major Dates

• Study Start (Estimated): December 1, 2023
• Primary Completion (Estimated): May 31, 2024
• Study Completion (Estimated): May 31, 2024

Study Registration Dates

• First Submitted: October 25, 2023
• First Submitted That Met QC Criteria: October 25, 2023
• First Posted (Actual): October 31, 2023

Study Record Updates

• Last Update Posted (Actual): November 30, 2023
• Last Update Submitted That Met QC Criteria: November 27, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Keywords: Rectal cancer; IL-2; Immunotherapy treatment
• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Intestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Colorectal Neoplasms; Rectal Neoplasms; Physiological Effects of Drugs; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Analgesics, Non-Narcotic; Antineoplastic Agents; Interleukin-2
• Other Study ID Numbers: PRSYM202310

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No